What the Data Says About NIH SBIR/STTR-Funded Companies
For biotech and medtech startups, NIH SBIR/STTR funding is often discussed as a way to finance research without giving up equity.
That is true, but it is only part of the story.
A National Academies assessment of the NIH SBIR/STTR programs found that funded companies also showed higher rates of venture capital activity, patenting, and publishing than applicants that were not funded.
The findings do not prove that an SBIR/STTR award caused those outcomes. Funded companies may have been stronger companies to begin with. But the data provide useful context for founders deciding whether pursuing NIH funding is worth the effort.
Funded companies were twice as likely to record venture capital funding
During the ten years following a company's first NIH SBIR/STTR application, venture capital appeared in:
4% of funded company-year observations
2% of unfunded applicant company-year observations
In other words, funded companies recorded venture capital activity at about twice the rate of unfunded applicants.
There was another difference.
When venture capital was raised, the median amount was:
$5 million for funded companies
$3.5 million for unfunded applicants
That is approximately 43% higher for funded companies.
For founders, the takeaway is not that an NIH award guarantees a venture round.
It is that SBIR/STTR funding can help a company generate the technical evidence and development progress that later financing often depends on.
Funded companies showed more than twice the patent activity
Patent activity also differed.
Patents appeared in:
9% of funded company-year observations
4% of unfunded applicant company-year observations
That works out to approximately 2.25 times the patent activity.
For a biotech or medtech company, that can matter. A stronger intellectual property position can support investor diligence, licensing discussions, strategic partnerships, and eventually acquisition value.
An SBIR/STTR project can be particularly useful when the funded work is expected to create new patentable technology or strengthen an existing platform.
Funded companies showed more than twice the publication activity
The same study found that publications appeared in:
26% of funded company-year observations
11% of unfunded applicant company-year observations
That is approximately 2.36 times the publication activity.
Publications are not the same thing as commercialization, but they can help establish scientific credibility and provide additional evidence supporting a technology.
That can be especially relevant for companies raising capital around a novel therapeutic, diagnostic, medical device, or research platform.
What founders should take from the data
Taken together, the findings are fairly straightforward:
NIH SBIR/STTR-funded companies showed:
2x the incidence of venture capital funding
43% higher median venture raises when funding occurred
2.25x the patent activity
2.36x the publication activity
These numbers should not be interpreted as guaranteed outcomes from receiving a grant.
The National Academies noted that funded companies also appeared stronger before receiving funding, so the analysis could not determine how much of the difference was caused by the award itself.
But for a biotech or medtech startup considering whether to pursue NIH SBIR/STTR funding, the findings are still relevant.
The program can provide non-dilutive capital to generate data, develop intellectual property, validate technology, and reach milestones that may matter in future investor and strategic-partner conversations.
The practical question
The question for a founder should not simply be:
"Can we apply for an SBIR?"
A better question is:
"Could SBIR/STTR funding help us reach a milestone that makes the company more valuable or easier to finance?"
If the answer is yes, the program may be worth pursuing.